-- Robert Preidt
WEDNESDAY, June 5 (HealthDay News) -- Drugs used to treat
early-stage Alzheimer's disease may also reduce patients' risk of
heart attack and death, according to a new study.
Researchers followed more than 7,000 Alzheimer's disease
patients in Sweden for more than three years. Those taking
cholinesterase inhibitors had a 38 percent lower risk of heart
attack, a 26 percent lower risk of death from cardiovascular causes
such as stroke and a 36 percent lower risk of death from any cause,
compared to those who did not take the drugs.
Patients who took the highest recommended doses of
cholinesterase inhibitors (ChEIs) had the lowest risk of heart
attack or death -- 65 percent and 46 percent lower, respectively,
than those who never took the drugs, according to the study, which
was published online June 5 in the
European Heart Journal.
"If you translate these reductions in risk into absolute figures, it means that for every 100,000 people with Alzheimer's disease, there would be 180 fewer heart attacks (295 as opposed to 475) and 1,125 fewer deaths from all causes (2,000 versus 3,125) every year among those taking ChEIs compared to those not using them," study author Professor Peter Nordstrom, of Umea University in Sweden, said in a journal news release.
No cure exists for Alzheimer's disease, an age-related brain
disorder and the most common form of dementia. However,
cholinesterase inhibitors, such as donepezil (brand name Aricept),
galantamine (Razadyne, Reminyl) and rivastigmine (Exelon), are
prescribed to help manage symptoms and slow disease progression in
people with early- to moderate-stage disease.
Previous research has found that these drugs have a beneficial
effect on the vagus nerve, which controls heart rate, and may have
"As far as we know, this is the first time that the use of ChEIs has been linked to a reduced risk of heart attacks and deaths from cardiovascular disease in general or from any cause," Nordstrom said.
"As this is an observational study, we cannot say that ChEI use is causing the reduction in risk, only that it is associated with a reduction," he said. "However, the strengths of the associations make them very interesting from the clinical point of view, although no clinical recommendations should be made on the basis of the results from our study."
An analysis of previous randomized, controlled trials would
produce answers on which clinical recommendations could be based,
The U.S. National Institute on Aging has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.